Target: Ret | Disease State: Cancer

Introduction / Brief Description

LOXO-292 is an oral and selective investigational new drug in clinical development for the treatment of patients with cancers that harbor abnormalities in the rearranged during transfection (RET) kinase. RET fusions and mutations occur across multiple tumor types with varying frequency. Genomic alterations in RET kinase, which include fusions and activating point mutations, lead to overactive RET signaling and uncontrolled cell growth. LOXO-292 is currently being studied in the global LIBRETTO-001 registration trial.

In July 2013, Array initiated a multi-year license and collaboration agreement with Loxo Oncology for certain Array-invented compounds, including Larotrectinib / LOXO-101, a Trk inhibitor; LOXO-292; and LOXO-195, a Trk inhibitor. In February 2019, Eli Lilly acquired Loxo Oncology. The licensing agreement between Array and Loxo remains in effect.

Clinical Trials

To learn more about LOXO-292 clinical trials, click here.

These compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview of our clinical trials.